|1.||Mizushima, Tohru: 4 articles (07/2014 - 01/2013)|
|2.||Yamashita, Yasunobu: 3 articles (07/2014 - 01/2013)|
|3.||Asano, Teita: 3 articles (07/2014 - 01/2014)|
|4.||Yamakawa, Naoki: 3 articles (07/2014 - 01/2013)|
|5.||Ishihara, Tomoaki: 3 articles (07/2014 - 01/2013)|
|6.||Kobayashi, Daisuke: 3 articles (07/2014 - 01/2013)|
|7.||Suzuki, Hidekazu: 3 articles (07/2014 - 01/2013)|
|8.||Tanaka, Ken-Ichiro: 3 articles (07/2014 - 01/2013)|
|9.||Sugizaki, Toshifumi: 2 articles (07/2014 - 01/2013)|
|10.||Kurotsu, Shota: 2 articles (07/2014 - 01/2014)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2013 - "Based on these results, we propose that mepenzolate bromide may be an effective therapeutic for the treatment of COPD due to its anti-inflammatory and bronchodilatory activities. "
07/01/2014 - "These results suggest that (R)-mepenzolate may have superior properties to (S)-mepenzolate as a drug to treat COPD patients given that the former has more potent bronchodilatory activity than the latter. "
01/01/2014 - "These results suggest that the pulmonary route of mepenzolate administration may be superior to other routes (oral, intravenous or intrarectal) to treat COPD patients. "
01/01/2014 - "Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease."
01/01/2013 - "Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease."
|3.||Pulmonary Fibrosis (Hamman Rich Syndrome)
07/01/2014 - "Ameliorative effect of mepenzolate bromide against pulmonary fibrosis."
07/01/2014 - "In the present study, we examined the effect of mepenzolate on bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. "
07/01/2014 - "These results show that the intratracheal administration of mepenzolate reduced bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. "
07/01/2014 - "Intratracheal administration of mepenzolate prior to bleomycin treatment reduced the extent of pulmonary fibrosis and changes in lung mechanics and led to a significant recovery of both FVC and SpO2 compared with control. "
|1.||mepenzolic acid (Cantil)
|2.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|3.||Pancreatic Elastase (Elastase)
|8.||methyl bromide (bromomethane)